Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
VDRM morning gapper above 3 cents IMO, chance for big run and lots of volume.
Going to be hard to buy shares today IMO
Could in fact happen!
Lets hope!
beautiful!
Indeed, great things are coming!!
Friday's PR dated 8/18/2017 shows where VDRM will be heading! 0.10+ very possible in short term IMO!
ViaDerma, Inc. Set to Begin Sales of its FDA Registered Topical Antibiotic in September with Initial Orders from Japan
Friday, August 18 2017 8:00 AM, EST Marketwire "Press Releases"
LOS ANGELES, CA -- (Marketwired) -- 08/18/17 --
ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, announced today that it has appointed Galaxy Solutions, Inc. as its sales representative for its first aid topical antibiotic which will be sold under the brand name Vitastem in select markets of Asia Pacific , starting in Japan . The agreement includes sales and marketing responsibilities of the Vitastem brand and possible other brands that will be developed for specific market segments.
Galaxy Solutions, Inc. will work to sell directly to larger customers and to distributors and will be the primary provider of service and support in the covered markets.
"With Galaxy Solutions as our sales representative, we will immediately have access to the professional segment of our target markets," said Dr. Chris Otiko, CEO of Viaderma, Inc. "Our goal is to continuously increase our revenues and improve our customers' experience in every aspect. Expanding our network of sales and support personnel and being in close proximity to where our customers are is a key initiative towards achieving that. With competitive pricing for retail sales through doctor's offices in Japan , the Company is conservatively estimating 2018 sales in Japan alone at approximately $12 million US dollars."
"Over the last 7 years Galaxy Solutions has established itself as a premier supplier of epidermal healing solutions, anti-aging solutions and beautification solutions. The relationship with Galaxy Solutions, Inc. will allow us to introduce our products to several markets, initially in Japan and then throughout Asia Pacific , immediately," said Otiko.
"Product testing has already begun and we are expecting to place an initial order in the next 30-45 days. I expect sales to be at around 10,000 units per month in the first 4-6 months and we hope to double that to 20,000 units per month in 2018 in Japan alone. The current testing is being done on sores resulting form side effects of cancer treatments and this will be our initial market, next we expect to introduce a product for acne," said Don Heath , President and CEO of Galaxy Solutions, Inc.
About ViaDerma, Inc.
ViaDerma, Inc. (OTC PINK: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma's products use an innovative transdermal delivery method that allows for application of active ingredients in a topical form. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets. Also, a patent application using the combination of CBD's and THC with the delivery system was filed in 2017. The use of CBD's is for the reduction of inflammation and for the treatment of several diseases, such as, nicotine addiction, fibromyalgia, Cohn's disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis. For more information, please visit: www.viadermalicensing.com.
About Galaxy Solutions, Inc.
Galaxy Solutions, Inc. is run by its CEO, Don Heath , a veteran in the area of product positioning and sales. After a successful career developing strategic global sales initiatives for fortune 100 companies in the 1980's, 90's and early 2000's, Don decided that he would move to Japan and set up his own Sales Representation company. Today, Don has developed deep relationships with retailers and distributors throughout Asia Pacific and has introduced many products to the Asia Pacific Market.
Forward-Looking Statements
Forward-Looking Statements certain statements in this release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified using words such as "anticipate," "believe," "expect," "future," "may," "will," "would," "should," "plan," "projected," "intend," and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. The Company's future operating results are dependent upon many factors, including but not limited to the Company's ability to: (i) obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; and (iv) other risk factors. We assume no obligation to update the information contained in this news release.
Contact information: Investor RelationsEmail: info@viadermalicensing.comPhone: 310-734-6111
Source: ViaDerma, Inc
VDRM
FDA approved products that ViaDerma (VDRM) offers:
-skin cancer therapies (Cantrile)
-stem cell therapy product (TetraStem Plus)
-topical antibiotics (TetraStem the world’s strongest broad-spectrum topical antibiotic available)
-TETRA-STEM – a tetracycline hydrochloride ointment. An award-winning antibiotic/wound healing product that kills all knows bacteria, including "flesh-eating" bacteria. Tertra-stem also can be used to treat wounds, ulcers
-topical anti-viral product (Viralcur) for genital herpes anti-fungal products for onychomycocis (OnyPro)
-hair loss prevention product (HairGain)
-ACNECLIR/ACNEEN – a salicylic acid based lotion that treats acne
-ECODERM – a colloidal oatmeal lotion for Eczema
-ACNECYCLINE – a tetracycline hydrochloride ointment that treats acne
-DERMONEEN – a salicylic acid lotion used to treat Psoriasis
-IVYMED – a zinc acetate based liquid that treats Poison Ivy rashes
- STAPHWASH PLUS – a zinc acetate based liquid. This is a non-antibiotic skin cleanser that kills MRSA
-TETRA-ABC – a tetracycline hydrochloride based ointment. This is an oil based topical antibiotic that kills all known bacterial infections. A water based version of this product is also available.
-STINGMED – a zinc acetate based liquid that treats most insect and spider bites
-ADVANCED JELLYFISH STING KIT – a zinc acetate powder, for suspension, that treats Jellyfish stings
-VENOMX – a zinc acetate based liquid used topically to treat snake bites.
-Product for treatment of Migraines presently; with a future of possibly ( inflammation of fibromyalgia, Cohn’s disease, nicotine addiction, schizophrenia, and pain management for Multiple Sclerosis and cancer. utilizing (CBD's) Calanoids and (THC) Tetrahydrocannabinol
biotechs trade at 30x earnings or 5x gross sales or 15x net sales or on air if they are a r and d company, with VDRM we have sales coming this year here is the analysis broken down below
ie...from the 500,000 bottles alone will yield $62.5M gross sales
$62.5m in gross sales X 5x gross sales = 325m market cap = $1.00 - $1.50 target
OR
62.5m in gross sales @ a 50% margin = $31m in net sales X 15x net sales = 450m market cap = $2.00 + target
OR
62.5m in gross sales with a $31m in net sales which divided by outstanding stock = 0.15 cents earnings X 30x earnings (pe - price to earnings) = $4.50 + target
Lead Product TetraStem
World’s strongest broad spectrum tetracycline-based topical antibiotic with proven results. Used for cuts, scrapes, wounds, infections, burns, acne, psoriasis, eczema, and minor injuries.
Very low water content and optimum (low) viscosity. Uses both a chemical AND physical kill mechanism which is advantageous over traditional antibiotics which use only a chemical kill mechanism and has a better resistance profile.
Potential Markets
ViaDerma is developing products in many fields of use, including:
Topical antibiotics- $6 billion/year
Toenail antifungal drugs- $3 billion/year
Diabetic amputations- $3 billion/year
Global acne- $3.02 billion/year
Psoriasis- $7.3 billion/year
Eczema- $2.5 billion/year
Other potential markets include burns, anti-aging/wrinkle remover cream, medical cannabis, male-pattern baldness, skin cancer, erectile dysfunction, and pain management. Innovative, patent pending dual carrier transdermal technology which can transformoral medication into topical products. Ability to enable active ingredients with a rapid transport direct to the site of action.
Ability to be used in any field including Sports Nutrition Supplements, Cosmetics, First Aid Products, Wound Care, and Skin Diseases like Acne, Eczema, and Psoriasis. Dual carrier liquid which can possess life enhancing technology with up to four year shelf-life. Facilitates transfer of chemicals through the stratum corneum with a diffusion constant 10,000x higher. Strong Advanced Biological Coverage (ABC) which has higher concentrations, faster penetration and is more effective than conventional antibiotics. ABC produces desirable results in ~24 hours or less compared to 5-7 days. It kills all harmful gram-positive and gram-negative bacteria that have been available for testing.
1- back in 2.25.2014 philips manufactured there last fda approval of tetrastem, its a 3 year shelf life as im able to see
2 - in 5.28.2014 VDRM started to manufacture there first fda approval of tetrastem, same 3 year shelf life
3 - now heres where it make huge sense in 3.2014 VDRM gets the rights to manufacture tetrastem from philips....1 month after they start there first manufacture of tetrastem
4 - the 3 - 6 - 9 month studies kick in in a huge way, and now VDRM as of 1.2017 manufactures 500,000 bottles for sale,
...basically they took what worked expanded on it and said this is huger than we thought
5 - 12.2016 VDRM files for updated Viabecline patent - which is purely application - so that means anyone, anywhere, anytime they use tetrastem - pure play on licensing application
6 - back in 2015 rumors started that both PFE and MRK and Endo pharma were looking at VDRM
7 - 2.2017 Dr Otiko to write a paper on diabetic ulcers showing massive results - which means all roads to viabecline
articles of interest ( get them off the web )
1 - from a 2.2011 study reposted in 1.2017 paraplegic uses tetrastem with stem cells and walks again ( philips put the article out )
2 - 3.2015 onychmycosis article
3 - 11.2016 viabecline article
4 - 12.2016 diabetic ulcers study vdrm issued
5 - 12.2016 viabecline patent applied for
6 - 1.2017 vdrm 500,000 bottles manufactured for 2017 grossing 62-65M in sales
viabecline is a delivery of tetrastem - which can take any oral as well and apply to ointment application
PFE is all about viagra, now imagine a lotion for f on f , not just a pill, and youve opened a huge market in the world away of same sex...mrk is all about diabetes and with application wise they want in too, add in JNJ which bandaids work and graduate to a 1000% increase in healing and they want in too...
VDRM product is 85% cheaper and works better - Viabecline is what the entire game is all about here - application technology
PFE Viagra is a category killer but it is a pill - and a pill is a introduction internally to the blood stream which out of fear a great portion of the population will just not take, now factor in a female Viagra alternative that is topical and replace the male Viagra with the same topical and its obvious that PFE will be forced to enter some sort of licensing agreement to hold onto there market share and as well look to capitalize on the female market as well ( m on f , and f on f ) there are those that will only use topical not internal
MRK, LLY and MNKD are the diabetic market and its huge - toenail fungal market - now add on a turnaround solution they have been needing for years, to treat at home foot infections ( home care largest market globally ) and that market alone is extraordinary with multiple companies all vying to be the dominant player and VDRM having the solution to license
JNJ marketplace is wounds - the band , now graduate it to the ability to speed the process up say 10 fold to heal any scrapes scratched wounds and to hold there market-share JNJ will be forced to enter some sort of licensing deal just to hold the line or risk crippling there empire quite easily
MRK and JNJ baldness market is in a level all itself, as its a do it yourself world we live in - add a just for men/ ladies crowd solution to expand into the baldness market and make that a CVS Walgreen's etc play for direct access more licensing
#11 on breakout boards!
Let's have a amazing day today!
Looking forward to jumping tax brackets soon
well let us know how it works ;)
Exactly, will be watching carefully
Nickel is likely tom IMO
Ah yes back then a spade was a spade and a beer was cold
All with a pack of camels at my desk
In your dreams baby
Very boring, too many shares outstanding going below .10 this week
Crooked mms
Oh the good old days
"The accompanying condensed consolidated financial statements have been prepared using the going concern basis of accounting, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.
As of June 30, 2017, the Company was in default on the repayment of certain convertible notes and promissory notes with an aggregate principal amount of $213,500, which are immediately due and payable. The continuation of the Company as a going concern through December 31, 2017 is dependent upon the continuing financial support from its stockholders or negotiation of repayment term. Management believes the existing shareholders will provide the additional cash to meet the Company’s obligations as they become due.
These factors raise substantial doubt about the Company’s ability to continue as a going concern. These consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets and liabilities that may result in the Company not being able to continue as a going concern."
This report is atrocious thus far
Ahh gotcha
Curious as to why it's in English though
Intriguing
Would be more likely to release tomorrow am than after 5 on a weekday IMO. Almost 5 in Cali
Yes it's shorting for me!
Yup agree, looks like it's barely hanging on
$VDRM POTENTIAL TO RUN TO 0.05 THIS WEEK!
Wowzer!
This won't go past 0.01
Great things to come folks this week and even beyond
Have fun and pump some iron! Will be getting sh i t faced trying to fast forward to tomorrow morning.
I think that is MORE than doable!
Absolutely. great things to come friend!
Agree 1000 percent! Time to drink some beers, unwind, and prep for tomorrow
Primed for a big day tomorrow! Predicting 25m in volume in first 2 hours
Come on baby lets close at 3 cents
+1000 truth
MOON IMMINENT FASTEN SEAT BELTS
45m in volune todays close very doable IMO